Exploratory Trial to Assess Mechanism of Action, Clinical Effect, Safety and Tolerability of 12 Weeks of Treatment With BI 655130 in Patients With Active Ulcerative Colitis (UC)
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs BI 655130 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 11 Jul 2017 Planned End Date changed from 1 May 2018 to 26 Jun 2018.
- 24 May 2017 Status changed from not yet recruiting to recruiting.
- 04 May 2017 Planned initiation date changed from 24 Apr 2017 to 22 May 2017.